EAM
REGN icon

Eagle Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Eagle Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4,411
Closed -$2.53M – 655
2020
Q3 		$2.53M Sell
4,411
-331
-7% -$201K 0.01% 420
2020
Q2 		$2.9M Buy
4,742
+1,956
+70% +$1.11M 0.02% 418
2020
Q1 		$1.36M Buy
+2,786
New +$1.15M 0.01% 499

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Eagle Asset Management's REGN Position: Q4 2020 in Review

Eagle Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2020, closing a stake of 4,411 shares — an estimated $2.53M sold.

Eagle Asset Management first reported a position in REGN in Q1 2020 and held it in 3 quarters. The position peaked at $2.9M in Q2 2020. 903 funds tracked by Wall St. Rank hold REGN as of Q4 2020.

  • Eagle Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Eagle Asset Management sold 4,411 Regeneron Pharmaceuticals shares in Q4 2020, an estimated $2.53M.
  • Eagle Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 3 quarters.
  • Eagle Asset Management's Regeneron Pharmaceuticals position peaked at $2.9M in Q2 2020.
  • 903 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2020.

Based on Eagle Asset Management's 13F filing for Q4 2020, filed 12 Feb 2021.